Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

NEXT STORY
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
PREV STORY
Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality

- Senior Pharmaceutical Industry Executive with Extensive Experience Leading Regulatory Affairs -WATERTOWN, Mass., Aug. ...

author_avatar
NASDAQ Market News

U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome

Intended for U.S. Audience U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application ...

author_avatar
NASDAQ Market News

Taking the Stage Today at the Consumer Electronics Show, a Hospital In Your Home

author_avatar
NASDAQ Market News